Navigate Up
Sign In


MSD and SwissCityMarathon Lucerne have again made a commitment to the marathon on 30 October by donating to the good cause the fees for 100 charity starts. The proceeds will go to the Make-A-Wish Switzerland foundation, which fulfils the dearest wishes of seriously ill children and their families. Find out more.
Read more.​

New Managing Director of MSD Switzerland​:
Dr. Thomas Lang has been appointed as the new Managing Director of MSD Switzerland. He is taking over the duties of P. Kyle Tattle, who assumes the position of Vice President, Customer Business Line, Oncology Asia Pacific at MSD, a globally leading research-based healthcare company. Read more.​

MSD welcomes new apprentices: In August, two young people take on their professional training as Laboratory Technicians EFZ (which will lead to a Certificate by the Swiss Confederation) in biology at Werthenstein BioPharma GmbH in Schachen and another school graduate will start his apprenticeship as a Business Administrator EFZ at MSD Merck Sharp & Dohme AG in Lucerne. With that, MSD is offering a total of eight recruits the opportunity of an apprenticeship in Switzerland.

​MSD in Switzerland

MSD is one of the world's leading healthcare companies, with its headquarters in the USA (Merck & Co., Inc., Kenilworth, NJ, USA). In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China. Welcome to MSD.

MSD as an employer 
To achieve our ambitious goals, we need the best possible specialist staff and highly committed employees. We offer various positions in a wide range of business areas like for example within our local and international sales organizations, research & development, manufacturing, and within the core departments of our global business located in Lucerne.
Find out more​


​The Antibiotics Challenge  

For more than 70 years, MSD has contributed to the discovery and development of novel medicines to combat infectious diseases. The combination with the bio-pharmaceutical company Cubist in January 2015 is an important milestone in this respect to intensify research in view of an increasing resistance against antibiotics – one of the biggest global health challenges - and develop innovative medicines for patients with potentially life-threatening infections diseases caused by bacteria. Cubist’s deep expertise and compelling portfolio and pipeline complement our broad portfolio of Hospital Acute Care. This will help advance a pipeline of candidates that hold the potential for making a meaningful difference in the lives of patients around the world.

General Remark:
Please be aware of the fact that each time when using one of the links in this website, you are leaving the Merck Sharp & Dohme AG, Switzerland (MSD), website and thus our sphere of responsibility. The linked Internet pages have their own terms of use and may be subject to different laws and standards.